FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo - Wikidata - awgldk - TriplyDB

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

http://www.wikidata.org/entity/Q34754329

about

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Childhood acute myeloid leukaemia Progress in acute myeloid leukemia An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment Targeted immunotherapy for acute myeloid leukemia Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.'Acute myeloid leukemia: a comprehensive review and 2016 update'FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.The Biology and Targeting of FLT3 in Pediatric Leukemia.BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.The Future of Targeting FLT3 Activation in AML.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Treatment of FLT3-ITD acute myeloid leukemia.Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic FLT3/ITD AML and the law of unintended consequences.Further activation of FLT3 mutants by FLT3 ligand Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation.Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.How I treat FLT3-mutated AML.

P2860

Q26749870-E1FC8881-6AF5-4B7D-A857-E5DB99D0D6D3 Q27005960-C17AC3F8-C47A-49FD-B94E-92FB371CAFFB Q27024006-ED9C45DB-C301-4721-B73B-EA376F2EE536 Q27027207-706A14D2-F7F0-4820-8EE5-24F279241C31 Q27687636-4618CE77-C809-4F9B-A76F-56931515EB3B Q27852520-C6EB0468-4904-4F04-A925-99FF7F6456E4 Q28072539-4814A785-897E-4B95-A712-931BC70E58A8 Q28289859-B85AFB79-D566-48B2-816B-CE0604209AD6 Q33767026-AC4331AB-4712-4478-8B4D-EC3A738D4B7C Q33774504-940E0196-442F-40A4-86EF-13A3B03E309E Q33838356-82EF7184-A699-4FC0-AC33-4846D6424CB5 Q33903030-E231DBED-E239-47CE-BAD2-566BB9C3021A Q33943277-E647C62C-E32F-4B3A-80F7-F4F0918EFF0D Q34004131-8D499A48-00DF-4A39-8DF6-EDF2B9711F58 Q34011740-5131B27C-3AE6-4DC4-B2CD-C558F66526C8 Q34229555-7AB2D7CE-ED91-4356-AF52-6CC29AB9924C Q34289202-BD323F41-AF63-4FDA-AF1C-20CC39335814 Q34555386-98941F8B-C059-4F1B-9601-C6C78FA741AD Q34620695-29DFDE57-A0D8-403C-8403-5FD940A5B49D Q34636735-BD53F9D4-AC00-4FF0-B55C-99417F8C260A Q34754344-BC231DCA-791D-4F95-B784-B019DF8AAB92 Q34817365-96B66DF7-56C4-416D-A27C-D06149F535E0 Q35127958-E71C98B1-E279-4EA7-8C3C-AF409C627AE8 Q35163307-690C9274-A37A-42D2-887F-486836D35A57 Q35224437-A9BC440C-DE65-4FC4-838D-E10636EBA324 Q35265916-8A64BF60-8EF0-4373-B386-F81806B444D8 Q35485832-5DC83BDF-2D44-47A2-996E-0F0168B82F55 Q35940547-F429FC88-7A10-4DD2-B657-473AED20ED38 Q36223356-C56E5B5B-AA55-4146-83E3-463FEA066E1D Q36276942-6FABC9A3-5306-4094-AF66-DF92000A0D60 Q36318153-850CE66D-B828-4BE1-A1B1-BB9A586A4CCF Q36693252-4874B79E-57C7-4162-9A60-BA508128E4E8 Q36907832-C1BD7A5E-7BDD-4841-90AA-AA2A8ED8C641 Q36949028-52208EB2-AC56-4753-9F72-69DD5D871FA7 Q37294768-F64D307A-60CE-4EF6-8BFE-69B76CC822FD Q37301761-1C5F1059-E345-42B8-8DC7-D95341C37AB7 Q37429734-6B711406-05B0-4C31-AF33-2D4BA1A95C8D Q37535249-551142CA-C3A2-4615-A9EA-2920866AEB55 Q37565024-28EE7313-BE4A-411B-93B3-FA04545CB93C Q37623389-80B95AF4-5FF1-4D43-AC9E-4A2B8AA4E4B3

P2860

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

http://www.wikidata.org/entity/Q34754329

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@ast

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@en

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@nl

type

label

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@ast

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@en

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@nl

prefLabel

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@ast

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@en

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@nl

P1433

Q34754329-8AD764E8-7B1F-497A-B517-E98D1AEBD283

P1476

Q34754329-89F72D0D-D0EC-446C-9B8B-6E5CB2578B0F

P2093

Q34754329-07212B13-2749-47FC-9DF3-BD317751A6F1

Q34754329-0C9F0F59-9A63-435D-9710-011B9165C1E0

Q34754329-60E1AE22-0059-46A1-8F53-923C7853387D

Q34754329-936692DE-A9A4-468A-A9A9-671FB3827242

Q34754329-AC9D5DD0-6C7A-435A-A590-2ACA65A50A0E

Q34754329-BD994563-8B16-4434-A022-9FEA76464A4A

Q34754329-DBAF98FA-AEA7-44A7-BB08-B071A173EDC3

Q34754329-E6DF8170-DADB-462D-8C8F-AEEF4F686A28

Q34754329-F162C299-34D1-4B51-940E-067A1531893D

P2860

Q34754329-04D6884B-3856-423E-BE86-689D35D3E5A7

Q34754329-0A8BC694-E50D-4D02-B0B5-B66A501C9A46

Q34754329-13F037BD-5F65-4EF3-B63B-C17E5E0499D9

Q34754329-1B2668C7-748E-4024-BB0C-38F53D20CC7E

Q34754329-26FA8DD2-4783-4E69-99E7-A2784C491C4C

Q34754329-279BA462-8A2C-4AC1-AE92-169E296481EE

Q34754329-2CB2C265-3FCD-4F12-810D-A045B3F5FA7C

Q34754329-421793A6-3965-4E28-B048-B4E6F05591D6

Q34754329-4FF7DEA1-54FB-4644-AF23-4FFAB0093FA4

Q34754329-5DA7CA39-5507-49DE-B577-D2BE6244BA07

P304

Q34754329-4D12154D-9B5A-4C39-803F-52C592661599

P31

Q34754329-512872E3-3ACD-44E3-BD2E-5BE61FAF0372

P356

Q34754329-EA7956A0-BDCD-4DB5-BBB4-2AEA448431AF

P407

Q34754329-AAE6616E-9ED7-4A09-BA83-AA8CCB04EB13

P433

Q34754329-1602F5C7-3561-45D2-BB5E-12D1D9FEDDD5

P478

Q34754329-CF160C33-E45A-4CCB-8A69-1563EB10F540

P577

Q34754329-2F5D1B68-5AC4-4676-A839-5643B3C57EBD

P5875

Q34754329-03CDC6EF-5484-42B5-BDEA-CD4326FD685C

P698

Q34754329-8CFCE6D2-9BFE-4868-AEDB-2618CD65CF95

P932

Q34754329-C4B29172-B7D0-403E-B737-730D98F794A8

P356

BLOOD-2010-01-266742

P1433

P1476

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

@en

P2093

Alan Burnett

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Donald Small

http://www.w3.org/2001/XMLSchema#string

Mark Levis

http://www.w3.org/2001/XMLSchema#string

Paul White

http://www.w3.org/2001/XMLSchema#string

Steven Galkin

http://www.w3.org/2001/XMLSchema#string

Steven Knapper

http://www.w3.org/2001/XMLSchema#string

Takashi Sato

http://www.w3.org/2001/XMLSchema#string

Xiaochuan Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Rational design of inhibitors that bind to inactive kinase conformations

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

The roles of FLT3 in hematopoiesis and leukemia.

P304

3286-3293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-01-266742

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49781862

http://www.w3.org/2001/XMLSchema#string

P698

21263155

http://www.w3.org/2001/XMLSchema#string

P932

3069670

http://www.w3.org/2001/XMLSchema#string